Arovella Therapeutics Limited Stock OTC Markets

Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. Its lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. It is also expanding into solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. It focuses on integrating IL-12-TM technology into its solid tumor programs.